DENTSPLY SIRONA Inkomsten in het verleden
Verleden criteriumcontroles 0/6
DENTSPLY SIRONA's earnings have been declining at an average annual rate of -41.1%, while the Medical Equipment industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 1.1% per year.
Belangrijke informatie
-41.1%
Groei van de winst
-41.3%
Groei van de winst per aandeel
| Medical Equipment Groei van de industrie | 8.9% |
| Inkomstengroei | 1.1% |
| Rendement op eigen vermogen | -5.9% |
| Nettomarge | -4.7% |
| Volgende winstupdate | 07 Nov 2024 |
Recente prestatie-updates uit het verleden
Recent updates
DENTSPLY SIRONA (NASDAQ:XRAY) Hasn't Managed To Accelerate Its Returns
Oct 13
DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Looks Inexpensive But Perhaps Not Attractive Enough
Sep 25Is It Time To Consider Buying DENTSPLY SIRONA Inc. (NASDAQ:XRAY)?
Sep 05Is There An Opportunity With DENTSPLY SIRONA Inc.'s (NASDAQ:XRAY) 21% Undervaluation?
Aug 18Returns On Capital At DENTSPLY SIRONA (NASDAQ:XRAY) Have Hit The Brakes
Jul 11A Tough Macro Environment Makes Dentsply Sirona's Turnaround Even Harder
Jul 02Insufficient Growth At DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Hampers Share Price
Jun 11We Think DENTSPLY SIRONA (NASDAQ:XRAY) Can Stay On Top Of Its Debt
May 24Dentsply Sirona: I'm Buying The Pullback In This Medtech Leader
Apr 24Are Investors Undervaluing DENTSPLY SIRONA Inc. (NASDAQ:XRAY) By 47%?
Apr 22There's No Escaping DENTSPLY SIRONA Inc.'s (NASDAQ:XRAY) Muted Revenues
Mar 10Here's Why DENTSPLY SIRONA (NASDAQ:XRAY) Has A Meaningful Debt Burden
Feb 16DENTSPLY SIRONA (NASDAQ:XRAY) Has More To Do To Multiply In Value Going Forward
Jan 29DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Shares Could Be 28% Below Their Intrinsic Value Estimate
Jan 11Is It Too Late To Consider Buying DENTSPLY SIRONA Inc. (NASDAQ:XRAY)?
Nov 25These 4 Measures Indicate That DENTSPLY SIRONA (NASDAQ:XRAY) Is Using Debt Extensively
Nov 06Returns On Capital At DENTSPLY SIRONA (NASDAQ:XRAY) Paint A Concerning Picture
Oct 15An Intrinsic Calculation For DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Suggests It's 46% Undervalued
Sep 18DENTSPLY SIRONA (NASDAQ:XRAY) Has A Pretty Healthy Balance Sheet
Jul 31The Returns At DENTSPLY SIRONA (NASDAQ:XRAY) Aren't Growing
Jul 09A Look At The Fair Value Of DENTSPLY SIRONA Inc. (NASDAQ:XRAY)
Jun 20When Should You Buy DENTSPLY SIRONA Inc. (NASDAQ:XRAY)?
Jun 02Investors Don't See Light At End Of DENTSPLY SIRONA Inc.'s (NASDAQ:XRAY) Tunnel
May 15The Returns At DENTSPLY SIRONA (NASDAQ:XRAY) Aren't Growing
Apr 05Is DENTSPLY SIRONA (NASDAQ:XRAY) Using Too Much Debt?
Mar 07We Think DENTSPLY SIRONA (NASDAQ:XRAY) Can Stay On Top Of Its Debt
Nov 09Dentsply Sirona names Glenn Coleman as new CFO
Sep 22Dentsply Sirona hires Simon Campion as president, CEO
Aug 25Dentsply Sirona receives noncompliance notice from Nasdaq
Aug 16Dentsply Sirona: Weakening Fundamentals Outweigh 'Defensives' Argument
Jul 18Opbrengsten en kosten
Opbrengsten en kosten
Hoe DENTSPLY SIRONA geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 3,896 | -185 | 1,596 | 172 |
| 31 Mar 24 | 3,940 | -95 | 1,611 | 180 |
| 31 Dec 23 | 3,965 | -132 | 1,617 | 184 |
| 30 Sep 23 | 3,936 | -214 | 1,611 | 184 |
| 30 Jun 23 | 3,936 | -1,025 | 1,641 | 179 |
| 31 Mar 23 | 3,931 | -1,038 | 1,638 | 175 |
| 31 Dec 22 | 3,922 | -950 | 1,596 | 174 |
| 30 Sep 22 | 4,042 | -816 | 1,564 | 180 |
| 30 Jun 22 | 4,135 | 345 | 1,552 | 178 |
| 31 Mar 22 | 4,174 | 368 | 1,536 | 176 |
| 31 Dec 21 | 4,231 | 411 | 1,547 | 171 |
| 30 Sep 21 | 4,207 | 401 | 1,535 | 166 |
| 30 Jun 21 | 4,062 | 370 | 1,458 | 154 |
| 31 Mar 21 | 3,491 | 179 | 1,323 | 129 |
| 31 Dec 20 | 3,339 | -73 | 1,309 | 123 |
| 30 Sep 20 | 3,371 | -80 | 1,275 | 210 |
| 30 Jun 20 | 3,438 | -48 | 1,340 | 183 |
| 31 Mar 20 | 3,957 | 84 | 1,510 | 165 |
| 31 Dec 19 | 4,022 | 256 | 1,578 | 143 |
| 30 Sep 19 | 3,977 | 162 | 1,520 | 161 |
| 30 Jun 19 | 3,944 | 105 | 1,560 | 161 |
| 31 Mar 19 | 3,976 | -1,053 | 1,562 | 161 |
| 31 Dec 18 | 3,986 | -1,011 | 1,551 | 161 |
| 30 Sep 18 | 4,018 | -1,663 | 1,560 | 152 |
| 30 Jun 18 | 4,098 | -1,601 | 1,578 | 152 |
| 31 Mar 18 | 4,049 | -1,529 | 1,563 | 152 |
| 31 Dec 17 | 3,993 | -1,550 | 1,532 | 152 |
| 30 Sep 17 | 3,899 | -793 | 1,501 | 129 |
| 30 Jun 17 | 3,844 | -791 | 1,443 | 129 |
| 31 Mar 17 | 3,873 | 365 | 1,427 | 129 |
| 31 Dec 16 | 3,745 | 430 | 1,374 | 129 |
| 30 Sep 16 | 3,420 | 382 | 1,307 | 75 |
| 30 Jun 16 | 3,115 | 374 | 1,192 | 75 |
| 31 Mar 16 | 2,791 | 312 | 1,065 | 75 |
| 31 Dec 15 | 2,674 | 251 | 993 | 75 |
| 30 Sep 15 | 2,722 | 277 | 1,011 | 81 |
| 30 Jun 15 | 2,782 | 268 | 1,017 | 81 |
| 31 Mar 15 | 2,849 | 314 | 1,038 | 81 |
| 31 Dec 14 | 2,923 | 323 | 1,062 | 81 |
| 30 Sep 14 | 2,957 | 313 | 1,061 | 85 |
| 30 Jun 14 | 2,953 | 317 | 1,060 | 85 |
| 31 Mar 14 | 2,949 | 314 | 1,054 | 85 |
| 31 Dec 13 | 2,951 | 313 | 1,060 | 85 |
Kwaliteitswinsten: XRAY is currently unprofitable.
Groeiende winstmarge: XRAY is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: XRAY is unprofitable, and losses have increased over the past 5 years at a rate of 41.1% per year.
Versnelling van de groei: Unable to compare XRAY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: XRAY is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (11.7%).
Rendement op eigen vermogen
Hoge ROE: XRAY has a negative Return on Equity (-5.91%), as it is currently unprofitable.